TDP-43 Protein

TDP-43 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TDP-43 — TAR DNA-Binding Protein 43</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TAR DNA-Binding Protein 43</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TARDBP](/genes/tardbp)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q7J653" target="_blank">Q7J653</a></td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1p36</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>RNA/DNA-binding protein (hnRNP family)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~44 kDa (414 aa)</td>
</tr>
<tr>
<td class="label">Key Diseases</td>
<td>[ALS](/diseases/als), [FTD](/diseases/ftd), [Alzheimer's](/diseases/alzheimers)</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">A382T, G348C, M337V, Q331K, G295S, D262G, N267S, K263E</td>
</tr>
</table>

TDP-43 Protein

Overview

TDP-43 (TAR DNA-Binding Protein 43) is a ubiquitously expressed RNA/DNA-binding protein encoded by the [TARDBP gene](/genes/tardbp) on chromosome 1p36. It is a member of the hnRNP (heterogeneous nuclear ribonucleoprotein) family and plays essential roles in RNA processing, splicing, and stress response [@tdp2006].

TDP-43 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TDP-43 — TAR DNA-Binding Protein 43</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TAR DNA-Binding Protein 43</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TARDBP](/genes/tardbp)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q7J653" target="_blank">Q7J653</a></td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1p36</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>RNA/DNA-binding protein (hnRNP family)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~44 kDa (414 aa)</td>
</tr>
<tr>
<td class="label">Key Diseases</td>
<td>[ALS](/diseases/als), [FTD](/diseases/ftd), [Alzheimer's](/diseases/alzheimers)</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">A382T, G348C, M337V, Q331K, G295S, D262G, N267S, K263E</td>
</tr>
</table>

TDP-43 Protein

Overview

TDP-43 (TAR DNA-Binding Protein 43) is a ubiquitously expressed RNA/DNA-binding protein encoded by the [TARDBP gene](/genes/tardbp) on chromosome 1p36. It is a member of the hnRNP (heterogeneous nuclear ribonucleoprotein) family and plays essential roles in RNA processing, splicing, and stress response [@tdp2006].

TDP-43 is central to the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and is commonly co-detected in [Alzheimer's disease](/diseases/alzheimers-disease) as a secondary pathology. Over 95% of ALS cases and approximately 50% of FTD cases show TDP-43 inclusions, making it one of the most important protein aggregation diseases in neurodegeneration [@neumann2009].

The discovery of TDP-43 as the major component of ubiquitin-positive inclusions in ALS and FTD in 2006 was a landmark in neurodegeneration research, unifying these previously distinct clinical entities under a common pathological mechanism [@tdp2006]. This finding has led to intense research into understanding TDP-43's normal functions and how dysregulation leads to disease.

Structure

Domain Architecture

TDP-43 is a 414-amino-acid protein with three major functional domains that work together to enable its diverse cellular functions:

1 100 200 300 414
|----------|----------|----------|-----------|
| N-term | RRM1 | RRM2 | Gly-rich |
| Dimer | RNA binding | Low-complexity|

• The two RRMs are highly conserved across species and share significant sequence similarity
• RRM1 and RRM2 together bind UG-rich RNA sequences with high affinity and specificity
• These domains shape alternative splicing decisions and regulate transcript stability
• RRM1 primarily mediates RNA binding, while RRM2 contributes to binding specificity
• The RRMs can also bind single-stranded DNA, though with lower affinity
• Mutations in the RRMs can impair RNA binding and contribute to disease [@arora2019]

• This region is intrinsically disordered and prone to liquid-liquid phase separation (LLPS)
• Mediates protein-protein interactions with numerous partners
• Controls stress granule dynamics and aggregation propensity
• Contains most disease-linked mutations (over 50 known pathogenic mutations)
• The prion-like properties of this domain enable templated aggregation
• This domain also contains Q/N-rich sequences that facilitate amyloid formation [@lester2023]

Three-Dimensional Structure

Cryo-EM studies have revealed that TDP-43 forms a dimer through interactions in the N-terminal domain, with the two RRM domains arranged in a dumbbell-like structure. The C-terminal domain is highly flexible and can adopt multiple conformations, which is relevant to its aggregation behavior. Recent studies have shown that TDP-43 aggregates in patient brains display conformational heterogeneity, suggesting distinct "strains" may underlie different clinical phenotypes [@tam2024].

Post-Translational Modifications

TDP-43 pathology is characterized by several post-translational modifications that serve as disease biomarkers:

• Phosphorylation: Pathological phosphorylation at Ser409/Ser410 is the hallmark of TDP-43 inclusions. This modification is mediated by casein kinase isoforms and is thought to promote aggregation while impairing degradation. Phospho-Ser409/410 antibodies are used diagnostically to detect TDP-43 pathology [@joardar2022].
• Ubiquitination: TDP-43 inclusions are ubiquitinated, marking them for proteasomal degradation. The ubiquitin ligase complex that modifies TDP-43 includes multiple enzymes, and ubiquitination may be both a cause and consequence of aggregation.
• C-terminal fragmentation: Proteolytic cleavage generates C-terminal fragments (approximately 25-35 kDa) that are highly aggregation-prone. These fragments are detected in patient brains and cerebrospinal fluid, serving as potential biomarkers.
• Acetylation: Acetylation at specific lysine residues in the RRM domains reduces RNA binding affinity and may contribute to loss-of-function in disease.
• Sumoylation: SUMO conjugation has been reported to modulate TDP-43 aggregation and may influence its nuclear-cytoplasmic shuttling.

Function

Nuclear Functions

TDP-43 is predominantly nuclear in healthy cells, where it functions as a master regulator of RNA metabolism.

RNA Splicing

TDP-43 is a master regulator of RNA splicing with thousands of RNA targets [@ratti2020]:

• Cryptic exon repression: One of TDP-43's most critical functions is repressing the inclusion of cryptic exons in pre-mRNA transcripts. Loss of nuclear TDP-43 leads to aberrant inclusion of cryptic exons, particularly in transcripts involved in neuronal function. This results in premature termination codons and transcript degradation [@singh2023].
• Long transcript stabilization: TDP-43 preferentially binds to long neuronal transcripts, many of which encode proteins involved in synaptic function, axonal guidance, and cytoskeletal organization. These transcripts are particularly vulnerable to TDP-43 loss-of-function.
• Alternative splicing: TDP-43 regulates the alternative splicing of hundreds of genes, influencing isoform expression patterns. It can act as both an activator and repressor of specific splice sites, depending on binding location and context.
• Synaptic program maintenance: TDP-43 controls the splicing of synaptic and cytoskeletal genes, ensuring proper expression of proteins required for neuronal connectivity and function.

Transcriptome Integrity

Loss of nuclear TDP-43 causes widespread transcriptome disruption [@arora2019]:

• Missplicing of critical neuronal transcripts leads to reduced protein expression
• Impaired synaptic function genes are particularly affected
• Cytoskeletal program disruption affects neuronal morphology
• Especially damaging in corticospinal and frontotemporal neurons
• The pattern of missplicing differs between ALS and FTD, suggesting distinct molecular mechanisms

Transcriptional Regulation

Beyond splicing, TDP-43 participates in:

• Transcriptional activation and repression through interaction with chromatin modifiers
• Regulation of long non-coding RNAs
• Telomere maintenance through binding to telomeric DNA
• Modulation of stress-responsive gene expression

Cytoplasmic Functions

Under stress conditions or in disease, TDP-43 redistributes to the cytoplasm where it performs additional functions.

Stress Granule Dynamics

Under cellular stress, TDP-43 translocates to stress granules [@tdp2019a]:

• TDP-43 is recruited to stress granules through its C-terminal low-complexity domain
• It participates in messenger RNP trafficking and local translation regulation
• TDP-43 remodels stress granule composition and dynamics
• Under chronic stress, granules become nucleation sites for pathological assemblies
• The transition from liquid-like granules to solid aggregates is a key disease step [@fallon2022]

RNA Transport

TDP-43 participates in:

• mRNA transport to neuronal processes via association with transport granules
• Local translation regulation at synapses
• Synaptic RNA homeostasis and activity-dependent translation
• The function of RNA transport is particularly important in long neurons like motor neurons

DNA Damage Response

Emerging evidence shows TDP-43 has important nuclear functions in DNA repair [@gao2018]:

• TDP-43 localizes to sites of DNA damage
• It couples RNA metabolism to repair pathways
• Loss of TDP-43 impairs DNA repair and increases genomic instability
• Mitochondrial TDP-43 affects oxidative stress response
• This function may explain the increased cancer risk observed in some TDP-43 models

Phase Separation and Aggregation

TDP-43 undergoes liquid-liquid phase separation (LLPS) through its C-terminal low-complexity domain [@lester2023]:

• Under normal conditions, TDP-43 forms liquid-like droplets
• Mutations and post-translational modifications can promote phase transition to solid aggregates
• The formation of stress granules is an example of functional LLPS
• Pathological aggregation represents a dysregulated form of phase separation
• This behavior is similar to other neurodegenerative disease proteins like TDP-43

Pathogenesis

TDP-43 Proteinopathy

TDP-43 aggregation follows a characteristic pattern that defines the disease:

This sequence of events leads to both loss-of-function (nuclear) and gain-of-toxicity (cytoplasmic) mechanisms.

ALS Mechanisms

Three coupled processes drive ALS pathogenesis [@arora2019]:

FTD Spectrum

TDP-43 pathology in FTD shows distinct patterns:

• FTLD-TDP subtypes A-D: Different anatomical patterns and pathological features characterize distinct subtypes. Subtype A shows neuronal cytoplasmic inclusions in layer II of the frontal cortex; subtype B shows widespread neuronal inclusions; subtype C shows neuronal intranuclear inclusions; subtype D shows dense inclusions in motor neurons.
• Behavioral variant FTD: Executive and social-cognitive impairment due to frontotemporal network degeneration
• Primary progressive aphasia: Language network degeneration, particularly affecting the left perisylvian region
• ALS-FTD overlap: Combined motor and cognitive phenotypes represent a disease spectrum

Alzheimer's Co-Pathology

TDP-43 is frequently detected in AD brains [@tdp2019]:

• Limbic TDP-43: Common in aging brain, affecting approximately 50% of AD cases
• LATE: Limbic-predominant age-related TDP-43 encephalopathy is now recognized as a distinct entity [@latenc2019]
• Cognitive impact: TDP-43 co-pathology independently accelerates memory decline
• Multi-proteinopathy: TDP-43 interacts with amyloid and tau pathology, potentially accelerating disease progression

Propagation and Spread

Recent research shows that TDP-43 pathology spreads through neural circuits [@pollock2024]:

• Template-based propagation of misfolded TDP-43 occurs
• The pattern of spread follows connectivity networks
• This prion-like mechanism explains the progressive clinical course
• Different strains may have varying propagation capacities

Clinical Significance

ALS (Amyotrophic Lateral Sclerosis)

• Pathology: >95% of ALS cases show TDP-43 inclusions [@neumann2009]
• Genetics: TARDBP mutations cause familial and sporadic ALS (1-3% of all cases) [@yang2024]
• Phenotype: Variable upper/lower motor neuron involvement
• Progression: Typically rapid progression, median survival 2-5 years
• Variants: Limb onset, bulbar onset, respiratory onset

Frontotemporal Dementia

• FTLD-TDP: Most common FTD pathological subtype (~50% of cases)
• Clinical variants: Behavioral, language, motor presentations
• Network vulnerability: Frontotemporal networks particularly affected
• Cognitive profile: Executive dysfunction, social comportment changes, language impairment

Alzheimer's Disease

• Co-pathology: TDP-43 detected in ~50% of AD brains [@latenc2019]
• LATE: Newly recognized entity affecting limbic structures
• Cognitive effects: Independent cognitive decline driver
• Therapeutic implications: Must consider in treatment design

Biomarkers

• CSF: Neurofilament light chain (NfL) elevated; TDP-43 fragments detectable
• Imaging: Network-based vulnerability patterns, frontotemporal atrophy
• Genetic testing: TARDBP mutation screening available
• Blood: Emerging blood-based biomarkers including pNfL and TDP-43 species

Other Associated Conditions

TDP-43 pathology is also seen in:

• Corticobasal degeneration: Approximately 50% of cases
• Progressive supranuclear palsy: Subset of cases
• Huntington's disease: Co-pathology in some cases
• Chronic traumatic encephalopathy: Co-occurrence with tau pathology

Therapeutic Strategies

Direct Targeting

• Antisense oligonucleotides (ASOs): Several ASOs targeting TARDBP mRNA have entered clinical trials. These reduce mutant TDP-43 expression while sparing wild-type. Current trials focus on reducing all TDP-43, as complete loss is not viable [@liu2023].
• RNA-binding modifiers: Small molecules that alter TDP-43-RNA interactions could restore proper splicing function
• Aggregation inhibitors: Block C-terminal aggregation through stabilization of native state or blocking amyloid formation
• Phase separation modulators: Targeting the LLPS behavior of TDP-43 could prevent pathological aggregation

Proteostasis Modulation

• Proteasome enhancers: Improve clearance of misfolded TDP-43 and aggregates
• Autophagy modulators: Enhance autophagy to clear inclusions. The lysosomal pathway is impaired in TDP-43 proteinopathy [@chiu2019].
• Integrated stress response: Modulate ISR pathways that are activated in TDP-43 depletion
• Molecular chaperones: Enhance chaperone activity to prevent aggregation

Gene Therapy Approaches

• Viral vector delivery of:
• Wild-type TARDBP to restore function
• RNA-targeted constructs to reduce toxic species
• Autophagy genes to enhance clearance
• Neuroprotective factors

Combination Approaches

• Neuroinflammation reduction: Target glial activation and reduce inflammatory cytokine release [@chen2023]
• Synaptic protection: Preserve synaptic function and prevent dendritic loss
• Metabolic support: Maintain energy homeostasis in affected neurons
• Neurotrophic factors: Support neuron survival and regeneration

Emerging Strategies

• Protein replacement: Delivery of functional TDP-43 protein
• Stem cell therapy: Replacing lost neurons or providing support cells
• Targeted degradation: Using PROTACs or molecular glues to eliminate toxic TDP-43
• Strain-specific therapies: Targeting specific aggregate conformations

Mutations

Pathogenic TARDBP Mutations

Over 50 pathogenic mutations in TARDBP have been identified, predominantly in the C-terminal domain [@tardbp2020]:

| Mutation | Location | Effect | Clinical Phenotype |
|----------|----------|--------|---------------------|
| A382T | C-terminal | Most common, ~50% of TARDBP ALS | ALS/FTD |
| M337V | C-terminal | Aggressive ALS, early onset | ALS |
| Q331K | C-terminal | ALS with dementia | ALS-FTD |
| G348C | C-terminal | FTD predominant | FTD |
| G295S | C-terminal | Classic ALS | ALS |
| D262G | C-terminal | ALS | ALS |
| N267S | C-terminal | Variable penetrance | ALS/FTD |
| K263E | C-terminal | ALS | ALS |
| A90K | N-terminal | Reduced penetrance | ALS |

Mutation Effects

• Aggregation propensity: Mutations in the C-terminal domain increase aggregation
• RNA binding: Some mutations alter RNA interactions and splicing function
• Stress granules: Mutant TDP-43 forms persistent granules that resist dissolution
• Phase separation: Mutations can alter LLPS behavior, promoting pathological transition
• Penetrance: Variable, with genetic modifiers affecting age of onset
• Phenotype correlation: Some mutations show phenotypic bias (ALS vs FTD)

Sporadic vs Familial

Both familial and sporadic ALS/FTD show TDP-43 pathology:

• Familial cases with TARDBP mutations show classic TDP-43 pathology
• Sporadic cases have TDP-43 pathology without known genetic cause
• The pathological mechanism is similar regardless of genetic basis
• This suggests a common final pathway in TDP-43 proteinopathy

Interactions

Protein Partners

TDP-43 interacts with numerous proteins that modulate its function [@ratti2020]:

| Partner | Interaction | Functional Effect |
|---------|-------------|-------------------|
| FUS | Co-aggregation | ALS spectrum, shared mechanisms |
| TIA1 | Stress granules | Stress response regulation |
| hnRNPs (A1, A2, A3) | Splicing complex | RNA processing |
| UBQLN2 | Autophagy | Protein clearance |
| p62 | Inclusion bodies | Degradation, selective autophagy |
| OPTN | Mitophagy | Mitochondrial quality control |
| VCP | Degradation | Proteostasis regulation |
| G3BP1 | Stress granules | Stress response |
| HDAC6 | Transport | Aggresome formation |

Signaling Pathways

TDP-43 influences multiple signaling pathways:

• RNA splicing: Cryptic exon repression through direct binding
• Stress response: Stress granule dynamics and composition
• Proteostasis: Protein quality control and degradation
• DNA damage: Repair pathway coupling
• Mitochondrial function:mtDNA maintenance and oxidative stress
• Cell death: Apoptosis and necroptosis pathways

Nucleic Acid Interactions

Beyond mRNA, TDP-43 binds:

• Long non-coding RNAs (lncRNAs)
• MicroRNAs (miRNAs)
• Telomeric DNA
• Mitochondrial transcripts
• Viral RNAs (potential role in infection-triggered disease)

Key Publications

See Also

• [TARDBP Gene](/genes/tardbp) — Gene-level information
• [ALS](/diseases/als) — Amyotrophic Lateral Sclerosis
• [FTD](/diseases/ftd) — Frontotemporal Dementia
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Associated disease
• [FUS Protein](/proteins/fus-protein) — Related ALS protein
• [Stress Granules](/mechanisms/stress-granules) — Pathological context
• [LATE-NC](/mechanisms/late-nc) — Limbic-predominant age-related TDP-43 encephalopathy

External Links

• [PubMed - TDP-43 Research](https://pubmed.ncbi.nlm.nih.gov/?term=TDP-43+ALS+FTD)
• [UniProt - TDP-43 (Q7J653)](https://www.uniprot.org/uniprot/Q7J653)
• [OMIM - TARDBP](https://www.omim.org/entry/605085)
• [ALS Association](https://www.als.org/)
• [Allen Human Brain Atlas - TARDBP Expression](https://human.brain-map.org/microarray/search/show?search_term=TARDBP)
• [Allen Mouse Brain Atlas - TDP-43](https://mouse.brain-map.org/)
• [Allen Cell Type Atlas - TDP-43](https://celltypes.brain-map.org/)

References

arora2019, TDP-43 and ALS: genetic and molecular insights (2019)
burke2020, Nuclear import of TDP-43 is mediated by importin-alpha (2020)
chen2023, TDP-43 drives neuroinflammation in ALS/FTD (2023)
chiang2019, Lysosomal dysfunction in TDP-43 proteinopathy (2019)
fallon2022, TDP-43 and stress granules in cellular models of ALS (2022)
gao2018, The role of TDP-43 in mitochondrial dysfunction in ALS (2018)
joardar2022, TDP-43 post-translational modifications in disease (2022)
latenc2019, LATE-NC: Limbic-predominant age-related TDP-43 encephalopathy (2019) [1](https://doi.org/10.1093/brain/awz099)
lester2023, TDP-43 phase separation and aggregation in neurodegeneration (2023)
liu2023, Therapeutic strategies targeting TDP-43 in ALS/FTD (2023)
manchester2020, TDP-43 aggregates show prion-like propagation (2020)
neumann2009, Pathological TDP-43 in neurodegenerative diseases (2009)
pollock2024, TDP-43 pathology spreads through neural circuits (2024)
ratti2020, TDP-43 functions in RNA metabolism and alternative splicing (2020)
singh2023, Cryptic exon inclusion in TDP-43 depletion models (2023)
tam2024, TDP-43 aggregates in the brain of ALS patients show conformational heterogeneity (2024)
tardbp2020, TARDBP mutations in ALS (2020) [1](https://doi.org/10.1016/j.neurobiolaging.2020.03.012)
tdp2006, TDP-43 in ALS and FTD (2006) [1](https://doi.org/10.1038/nature05349)
tdp2019, TDP-43 pathology in Alzheimer's disease (2019) [1](https://doi.org/10.1038/s41582-019-0228-7)
tdp2019a, TDP-43 stress granules in neurodegeneration (2019) [1](https://doi.org/10.1016/j.tcb.2019.04.011)
yang2024, Novel TARDBP mutations in ALS patients (2024)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
• [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
• [Serine/Arginine-Rich Protein Kinase Modulation](/hypothesis/h-dca3e907) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SRPK1
• [Low Complexity Domain Cross-Linking Inhibition](/hypothesis/h-69d383ea) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: TGM2

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;